Analysis of ABL kinase domain mutations as a probable cause of imatinib resistance in Chronic Myeloid Leukemia patients of Kashmir

No imatinib resistance mutations were detected in the patients either at baseline or across all the follow-up durations implying other causes for imatinib resistance in CML patients of our region.